4D Molecular Therapeutics FDMT Contract Liabilities, Non-Current
Contract Liabilities, Non-Current at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's contract liabilities, non-current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's contract liabilities, non-current?
- 4D Molecular Therapeutics (FDMT) reported contract liabilities, non-current of $2.13M in Q1 2026.
- How has 4D Molecular Therapeutics's contract liabilities, non-current changed year-over-year?
- 4D Molecular Therapeutics's contract liabilities, non-current increased by 389.6% year-over-year, from $434K to $2.13M.
- What is the long-term trend for 4D Molecular Therapeutics's contract liabilities, non-current?
- Over 5 years (2020 to 2025), 4D Molecular Therapeutics's contract liabilities, non-current has grown at a -43.7% compound annual growth rate (CAGR), from $13.23M to $745K.